The panel consensus is that while KO and JNJ are typically considered defensive stocks, their current valuations and potential risks make them less attractive as crash-proof investments. The panelists also highlighted the risks associated with JNJ's post-spinoff structure and the potential impact of litigation and regulatory pricing on earnings.
Risk: Earnings multiple compression in a downturn due to input cost spikes, litigation overhang, and potential drug price negotiations for JNJ.
Opportunity: JNJ's potential pivot towards higher-growth segments in oncology and surgery, if successfully executed.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Key Points
- These market leaders have been around for a very long time.
- Both have reliable underlying businesses and outstanding dividend track records.
- 10 stocks we like better than Coca-Cola ›
Some investors are worried that a recession is coming. That's not at all outside the realm of possibilities. After all, ongoing geopolitical tensions …
Read more
Key Points
- These market leaders have been around for a very long time.
- Both have reliable underlying businesses and outstanding dividend track records.
- 10 stocks we like better than Coca-Cola ›
Some investors are worried that a recession is coming. That's not at all outside the realm of possibilities. After all, ongoing geopolitical tensions have already affected the economy through higher oil and energy prices and elevated inflation. Perhaps things will get even worse and eventually send broader equities into bear market territory. Though we can't predict that for certain, we can prepare for this possibility by investing in recession-resistant stocks. Here are two excellent options to consider: Coca-Cola (NYSE:KO) and Johnson & Johnson (NYSE:JNJ).
Image source: The Motley Fool.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
1. Coca-Cola
Coca-Cola is well over 100 years old, a feat few corporations have ever achieved. The company has lasted that long partly by becoming a household name. Everyone knows the Coca-Cola brand and logo, which grants the company a significant marketing advantage. Another factor behind Coca-Cola's longevity is that it belongs to a defensive industry: Consumer staples. The "staple" here refers to goods people tend to buy regardless of economic conditions. Coca-Cola's beverages belong to that group.
None of this means Coca-Cola's business will navigate a recession completely unscathed. But the beverage maker has the tools to get through economic downturns relatively well. We can also highlight Coca-Cola's dividend program. The company has increased its payouts for 64 consecutive years, making it a Dividend King, or a company with at least 50 straight annual dividend hikes. Dividends provide a regular stream of income that helps cushion market losses during downturns. Just as important, Coca-Cola's dividend streak provides more evidence of its resilience.
Some dividend stocks suspend their payouts when the going gets rough, but Coca-Cola has grown its dividends for more than six decades, a period that includes several recessions and many other marketwide challenges. It's no wonder, then, that Coca-Cola's shares are hardly cheap when going by traditional valuation metrics. The company is trading at 25.2x forward earnings, versus an average of 21x for consumer staples stocks. However, Coca-Cola is worth the premium, especially for income seekers building a recession-resistant portfolio.
2. Johnson & Johnson
Johnson & Johnson has also been around for over 100 years and has established itself as an undisputed leader in healthcare, a defensive sector that nevertheless evolves quickly and can leave behind companies that fail to innovate. But Johnson & Johnson has been, and continues to be, an innovator.
The company boasts a large portfolio of pharmaceutical products across several therapeutic areas, with particular strength in oncology and immunology, two of the largest markets in the industry. Johnson & Johnson's diversified product lineup and deep pipeline mean it can earn brand-new approvals and label expansions fairly regularly while navigating challenges like losses of patent exclusivity fairly well.
The company is also a leader in medical devices, marketing products across cardiovascular health, surgery, orthopedics, and vision care. Even when some of the company's segments encounter challenges -- including during recessions -- others should perform well and pull the company average in the right direction. That's the advantage of diversification.
Johnson & Johnson faces risks, including government drug price negotiations that could lead to lower sales for some of its products in the U.S. and the thousands of lawsuits alleging that its talc-based products caused cancer. However, the company is well equipped to handle both obstacles. It is growing its revenue at a good clip this year, despite a financial hit on some products due to government drug negotiations.
Also, Johnson & Johnson recently reached a proposed $5.5 billion settlement of its remaining ovarian talc litigation, though it is subject to certain conditions. Even if this proposed settlement falls through, the company has a rock-solid balance sheet with an AAA credit rating -- the highest rating -- from S&P Global. Finally, Johnson & Johnson is also a Dividend King with 64 consecutive annual payout raises. The stock would be a great safe haven during a recession.
Should you buy stock in Coca-Cola right now?
Before you buy stock in Coca-Cola, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Coca-Cola wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $395,625! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,397,147!
Now, it’s worth noting Stock Advisor’s total average return is 951% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of September 23, 2026. *
Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
“Defensive positioning helps, but valuation, legal/regulatory tail risks, and real-economy stress must be validated before assuming material upside.”
Today's piece leans on KO and JNJ as fail-safe picks in a downturn, citing brand moat, dividend streaks, and defensive sector walls. The logic is sound but incomplete: valuations are rich for KO (forward P/E around mid-20s vs staples average ~21x) and JNJ trades at premium credit-quality expectations. Even defensives can compress if the macro shock is deep, inflation persists, or input costs squeeze margins (sugar, aluminum, talc fines, or drug-price reforms). JNJ's talc litigation and potential price negotiations, plus potential drug-reform risk, can limit upside. A crash-safe thesis should test balance-sheet resilience, dividend sustainability, and scenario-based earnings under more severe stress.
KO and JNJ might be more vulnerable than suggested: a deep recession could pressure consumer staples pricing power if unemployment spikes, and JNJ's talc/legal/regulatory headwinds could surprise to the downside.
“Valuing defensive stocks at 25x forward earnings creates significant downside risk if they fail to provide the expected growth premium during a contraction.”
While the article correctly identifies KO and JNJ as defensive staples, it ignores the 'bond proxy' trap. At 25.2x forward earnings, KO is priced for perfection, not for the margin compression that occurs when input costs spike during stagflation. Investors chasing these 'Dividend Kings' often overlook that in a true market crash, these stocks frequently suffer from multiple contraction as investors rotate into actual risk-free assets like Treasuries. JNJ, while diversified, faces significant long-term litigation overhang and R&D efficiency risks that a simple AAA credit rating doesn't fully mitigate. These aren't 'buy hand over fist' opportunities; they are expensive defensive plays that offer limited upside in a recovery.
If interest rates fall rapidly during a recession, the yield gap between these Dividend Kings and fixed income will widen, potentially driving a valuation re-rating that justifies current premiums.
“Buying defensive stocks at premium valuations in anticipation of a crash you cannot time is a value trap dressed as prudence.”
This article conflates two separate theses without evidence. Yes, KO and JNJ are defensive—that's true. But the article never demonstrates that a crash is *coming*, only that one *could* happen. More problematically: KO trades at 25.2x forward P/E (vs. 21x sector average) on the premise of recession resilience, yet defensive premiums typically *compress* during downturns as growth stocks recover. JNJ's 64-year dividend streak is real, but the article ignores that pharma faces structural headwinds: drug price negotiations are accelerating, patent cliffs loom, and the talc settlement ($5.5B) assumes no further litigation. Neither stock is cheap enough to justify buying 'hand over fist' on defensive merit alone.
If a genuine recession hits within 12 months, both stocks' dividend stability and market share moats could outperform by 500+ bps—and the 25x multiple on KO might be justified by flight-to-safety flows that override valuation discipline.
“Premium valuations plus litigation and pricing risks make aggressive buying of these names ahead of a crash less compelling than the article claims.”
The article frames KO and JNJ as crash-proof buys due to their Dividend King status and defensive exposure in staples and healthcare. KO's 25.2x forward P/E already prices in resilience, leaving little margin if volume growth slows or input costs rise. JNJ's AAA balance sheet helps, but the $5.5B talc settlement and Medicare price negotiations create near-term earnings uncertainty the piece downplays. Both stocks have survived past recessions, yet current multiples and macro headwinds like elevated rates suggest limited upside if a downturn materializes.
Their 64-year dividend streaks and sector stability have repeatedly cushioned drawdowns, so even at premium valuations they could still outperform cyclicals in a real recession.
The Debate
Responding to Gemini
“Post-spinoff liability allocation could erode the defensive premium and trigger multiple compression in a crisis if core JNJ bears the bulk of legacy liabilities.”
While I agree KO's earnings multiple is rich, Gemini highlights a real 'bond proxy' risk. A sharper overlooked angle is how J&J's post-spinoff structure could alter risk attribution. If talc/legacy liabilities remain with core JNJ instead of the spun-off entity, downside risk in litigation and regulatory pricing could rekindle sizable earnings volatility, compress multiples, and threaten the defense premium in a true crisis.
Responding to Claude
“JNJ's valuation may be justified by a strategic pivot to high-growth med-tech rather than just its defensive status.”
Claude is right to challenge the 'crash-proof' narrative, but we are missing the capital allocation shift. JNJ’s recent spin-off of Kenvue and its aggressive M&A strategy in med-tech suggest a pivot toward higher-growth, higher-margin segments that the market hasn't fully priced in. While litigation remains a drag, if JNJ successfully pivots to high-growth oncology and surgery, the current valuation isn't just a defensive premium—it's a fundamental re-rating waiting to happen, provided they execute.
Responding to Gemini
“JNJ's post-spinoff structure actually *increases* downside risk in a downturn by concentrating exposure to pharma headwinds while removing consumer staples ballast.”
Gemini's M&A pivot thesis is speculative—JNJ's oncology/surgery upside depends entirely on execution, which isn't guaranteed. More critically: the Kenvue spinoff *reduced* JNJ's defensive profile by shedding consumer staples. If a recession hits, JNJ becomes a pure-play pharma with litigation drag, not a diversified defensive. Current valuation assumes both the pivot *and* no earnings surprises. That's two bets, not one.
Responding to Claude
“JNJ's post-spinoff structure concentrates regulatory and pipeline risks, making the current valuation less defensible than assumed.”
Claude flags the Kenvue spinoff correctly, yet the deeper issue is how this leaves JNJ exposed to reimbursement cycles and patent-cliff timing that staples never carried. Medicare price negotiations now hit a narrower earnings base, and any delay in oncology approvals could force multiple compression faster than the 25x forward multiple anticipates. The litigation overhang stays concentrated without the prior diversification buffer.
Panel Verdict
NEUTRAL No ConsensusThe panel consensus is that while KO and JNJ are typically considered defensive stocks, their current valuations and potential risks make them less attractive as crash-proof investments. The panelists also highlighted the risks associated with JNJ's post-spinoff structure and the potential impact of litigation and regulatory pricing on earnings.
JNJ's potential pivot towards higher-growth segments in oncology and surgery, if successfully executed.
Earnings multiple compression in a downturn due to input cost spikes, litigation overhang, and potential drug price negotiations for JNJ.
This is not financial advice. Always do your own research.